1Pannu HK, Horton KM, Fishman EK. Thin section dual-phase multidetector-row computed tomography detection of peritoneal metastases in gynecologic cancers. J Comput Assist Tomogr, 2003, 27(3):333-340
2Forstner R, Hricak H, Powell CB, et al. Ovarian cancer recurrence: value of MR imaging. Radiology, 1995, 196(3):715-720
3Low RN, Saleh F, Song SYT, et al. Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination: a longitudinal study. Radiology, 1999, 211(2):519-528
4Ricke J, Sehouli J, Hach C, et al. Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol, 2003, 13(5):943-949
5Chang WC, Hung YC, Kao CH, et al. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker (CA-125 antigen). Neoplasma, 2002, 49(5):329-333
6Menzel C, Dobert N, Hamscho N, et al. The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer. Strahlenther Onkol, 2004, 180(8):497-501
7Drieskens O, Stroobants S, Gysen M, et al. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer. Gynecol Obstet Invest, 2003, 55(34):130-134
8Pannu HK, Cohade C, Bristow RE, et al . PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation. Abdom Imaging, 2004, 29(3): 398-403
9Sironi S, Messa C, Mangili G, et al.Integrated FDG PET/CT in patients with persistent ovarian cancer:correlation with histologic findings.Radiology, 2004,233(2):433-440
10Torizuka T, Kanno T,Futatsubashi M, et al. Imaging of gynecologic tumors: Comparison of (11)C-choline PET with (18)F-FDG PET.J Nucl Med, 2003, 44(7):1051-1056
